Sentiment-Signal
16,9
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 19.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 14.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ¨ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Ap |
| 12.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 13.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Off |
| 02.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Comp |
Stammdaten
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Unternehmen & Branche
| Name | GILEAD SCIENCES, INC. |
|---|---|
| Ticker | GILD |
| CIK | 0000882095 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - General |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 160,00 Mrd. USD |
| Beta | 0,40 |
| Dividendenrendite | 3,19 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 29,443,000,000 | 8,510,000,000 | 6.78 | 59,023,000,000 | 22,703,000,000 |
| 2025-09-30 | 10-Q | 7,769,000,000 | 3,052,000,000 | 2.43 | 58,533,000,000 | 21,540,000,000 |
| 2025-06-30 | 10-Q | 7,082,000,000 | 1,960,000,000 | 1.56 | 55,721,000,000 | 19,674,000,000 |
| 2025-03-31 | 10-Q | 6,667,000,000 | 1,315,000,000 | 1.04 | 56,434,000,000 | 19,162,000,000 |
| 2024-12-31 | 10-K | 28,754,000,000 | 480,000,000 | 0.38 | 58,995,000,000 | 19,330,000,000 |
| 2024-09-30 | 10-Q | 7,545,000,000 | 1,253,000,000 | 1.00 | 54,525,000,000 | 18,475,000,000 |
| 2024-06-30 | 10-Q | 6,954,000,000 | 1,614,000,000 | 1.29 | 53,579,000,000 | 18,281,000,000 |
| 2024-03-31 | 10-Q | 6,686,000,000 | -4,170,000,000 | -3.34 | 56,292,000,000 | 17,539,000,000 |
| 2023-12-31 | 10-K | 27,116,000,000 | 5,665,000,000 | 4.50 | 62,125,000,000 | 22,833,000,000 |
| 2023-09-30 | 10-Q | 7,051,000,000 | 2,180,000,000 | 1.73 | 62,373,000,000 | 22,314,000,000 |
| 2023-06-30 | 10-Q | 6,599,000,000 | 1,045,000,000 | 0.83 | 62,337,000,000 | 21,158,000,000 |
| 2023-03-31 | 10-Q | 6,352,000,000 | 1,010,000,000 | 0.80 | 61,876,000,000 | 20,997,000,000 |
| 2022-12-31 | 10-K | 27,281,000,000 | 4,592,000,000 | 3.64 | 63,171,000,000 | 21,240,000,000 |
| 2022-09-30 | 10-Q | 7,042,000,000 | 1,789,000,000 | 1.42 | 62,557,000,000 | 21,081,000,000 |
| 2022-06-30 | 10-Q | 6,260,000,000 | 1,144,000,000 | 0.91 | 62,870,000,000 | 20,236,000,000 |
| 2022-03-31 | 10-Q | 6,590,000,000 | 19,000,000 | 0.02 | 63,080,000,000 | 19,927,000,000 |
| 2021-12-31 | 10-K | 27,305,000,000 | 6,225,000,000 | 4.93 | 67,952,000,000 | 21,069,000,000 |
| 2021-09-30 | 10-Q | 7,421,000,000 | 2,592,000,000 | 2.05 | 67,098,000,000 | 21,470,000,000 |
| 2021-06-30 | 10-Q | 6,217,000,000 | 1,522,000,000 | 1.21 | 67,984,000,000 | 19,703,000,000 |
| 2021-03-31 | 10-Q | 6,423,000,000 | 1,729,000,000 | 1.37 | 67,492,000,000 | 18,952,000,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -6,950 | 128.79 | -895,074.52 | -74,6% | |
| 2026-04-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -3,050 | 130.01 | -396,533.86 | -33,1% | |
| 2026-04-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3,000 | 140.96 | -422,880.00 | -35,3% | |
| 2026-04-15 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -3,000 | 140.96 | -422,880.00 | -35,3% | |
| 2026-03-27 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -10,000 | 136.82 | -1,368,162.00 | -114,1% | |
| 2026-03-16 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3,000 | 144.23 | -432,690.00 | -36,1% | |
| 2026-03-16 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -3,000 | 144.23 | -432,690.00 | -36,1% | |
| 2026-02-27 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -3,481 | 144.04 | -501,386.18 | -41,8% | |
| 2026-02-27 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -6,419 | 145.18 | -931,901.43 | -77,7% | |
| 2026-02-27 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -100 | 145.71 | -14,571.00 | -1,2% | |
| 2026-02-17 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -200 | 155.62 | -31,124.00 | -2,6% | |
| 2026-02-17 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3,000 | 154.43 | -463,290.00 | -38,6% | |
| 2026-02-17 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -18,405 | 154.18 | -2,837,719.71 | -236,6% | |
| 2026-02-17 | Mercier Johanna | Officer, Chief Comm & Corp Aff Officer | Open Market Sale | -9,395 | 154.91 | -1,455,384.15 | -121,3% | |
| 2026-02-05 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -115,640 | 150.00 | -17,346,000.00 | -1446,2% | |
| 2026-01-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -5,032 | 139.54 | -702,185.91 | -58,5% | |
| 2026-01-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -4,968 | 140.24 | -696,725.24 | -58,1% | |
| 2026-01-23 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -115,640 | 135.00 | -15,611,400.00 | -1301,5% | |
| 2026-01-20 | Bluestone Jeffrey | Director | Open Market Sale | -5,000 | 123.50 | -617,500.00 | -51,5% | |
| 2026-01-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3,000 | 124.31 | -372,930.00 | -31,1% | |
| 2026-01-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3,000 | 124.31 | -372,930.00 | -31,1% | |
| 2025-12-29 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -10,000 | 124.83 | -1,248,272.00 | -104,1% | |
| 2025-12-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3,000 | 122.00 | -366,000.00 | -30,5% | |
| 2025-12-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -3,000 | 122.00 | -366,000.00 | -30,5% | |
| 2025-11-28 | Kramer Kelly A. | Director | Open Market Sale | -2,805 | 127.10 | -356,515.50 | -29,7% | |
| 2025-11-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -6,788 | 126.84 | -861,015.71 | -71,8% | |
| 2025-11-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -3,212 | 125.91 | -404,428.06 | -33,7% | |
| 2025-11-28 | Bluestone Jeffrey | Director | Open Market Sale | -5,000 | 125.08 | -625,400.00 | -52,1% | |
| 2025-11-26 | Kramer Kelly A. | Director | Open Market Sale | -2,806 | 127.11 | -356,670.66 | -29,7% | |
| 2025-11-17 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -25,524 | 125.83 | -3,211,559.85 | -267,8% | |
| 2025-11-17 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -2,476 | 126.26 | -312,613.57 | -26,1% | |
| 2025-11-17 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2,500 | 125.23 | -313,075.00 | -26,1% | |
| 2025-11-12 | Telman Deborah H | Officer, EVP, Corporate Affairs & GC | Open Market Sale | -35,965 | 122.30 | -4,398,591.43 | -366,7% | |
| 2025-11-12 | Telman Deborah H | Officer, EVP, Corporate Affairs & GC | Open Market Sale | -500 | 122.90 | -61,452.00 | -5,1% | |
| 2025-11-12 | Telman Deborah H | Officer, EVP, Corporate Affairs & GC | Open Market Sale | -17,181 | 124.00 | -2,130,444.00 | -177,6% | |
| 2025-10-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -7,978 | 119.54 | -953,666.98 | -79,5% | |
| 2025-10-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -2,022 | 118.82 | -240,258.69 | -20,0% | |
| 2025-10-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3,000 | 118.08 | -354,240.00 | -29,5% | |
| 2025-10-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2,500 | 118.08 | -295,200.00 | -24,6% | |
| 2025-09-29 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -1,961 | 112.42 | -220,454.25 | -18,4% | |
| 2025-09-29 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -8,039 | 111.47 | -896,109.74 | -74,7% | |
| 2025-09-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3,000 | 113.57 | -340,710.00 | -28,4% | |
| 2025-09-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2,500 | 113.57 | -283,925.00 | -23,7% | |
| 2025-08-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -10,000 | 113.63 | -1,136,300.00 | -94,7% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -700 | 118.97 | -83,278.02 | -6,9% | |
| 2025-08-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2,500 | 118.53 | -296,325.00 | -24,7% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -11,800 | 118.51 | -1,398,405.02 | -116,6% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -11,800 | 118.50 | -1,398,351.92 | -116,6% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -2,800 | 118.51 | -331,820.72 | -27,7% | |
| 2025-08-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -200 | 118.97 | -23,793.00 | -2,0% | |
| 2025-07-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -8,345 | 114.09 | -952,076.88 | -79,4% | |
| 2025-07-28 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -1,655 | 113.17 | -187,292.71 | -15,6% | |
| 2025-07-15 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3,000 | 111.03 | -333,090.00 | -27,8% | |
| 2025-07-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2,500 | 111.03 | -277,575.00 | -23,1% | |
| 2025-07-14 | Bluestone Jeffrey | Director | Open Market Sale | -5,000 | 109.74 | -548,700.00 | -45,7% | |
| 2025-06-30 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -9,400 | 110.40 | -1,037,795.72 | -86,5% | |
| 2025-06-30 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -600 | 111.15 | -66,688.02 | -5,6% | |
| 2025-06-16 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2,500 | 110.17 | -275,425.00 | -23,0% | |
| 2025-06-16 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3,000 | 110.17 | -330,510.00 | -27,6% | |
| 2025-05-30 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -6,416 | 110.11 | -706,496.56 | -58,9% | |
| 2025-05-30 | O'Day Daniel Patrick | Director, Officer, Chairman & CEO | Open Market Sale | -3,584 | 110.96 | -397,696.05 | -33,2% | |
| 2025-05-22 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -3,000 | 107.52 | -322,563.60 | -26,9% | |
| 2025-05-22 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -12,500 | 107.52 | -1,344,038.75 | -112,1% | |
| 2025-05-22 | Mercier Johanna | Officer, Chief Commercial Officer | Open Market Sale | -12,500 | 107.52 | -1,343,961.25 | -112,0% | |
| 2025-05-15 | Dickinson Andrew D | Officer, Chief Financial Officer | Open Market Sale | -2,500 | 99.82 | -249,550.00 | -20,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.